ALZselftest provides early screening of cognitive impairment with 98% accuracy
Developed by Dr. John H. Dougherty, a leading neurologist, founder of Medinteract, LLC and Medical Director of the Cole Neuroscience Center at UT Medical Center in Knoxville, the ALZselftest empowers people to monitor their cognitive health and identify potential problems as early as possible.
In 2002, Dr. Dougherty developed the Self Test, a paper test designed to identify cognitive impairment at the earliest possible stages. Due to the alarming rate of Alzheimer's Disease sufferers going undiagnosed, Dr. Dougherty has adapted his existing test for computer use, and has made it available directly to the public online.
According to the National Institute on Aging, scientists estimate 4.5 million Americans currently suffer from Alzheimerâ€™s Disease. "The earlier you diagnose Alzheimer's Disease, the better your chances of managing the disease without severe impairment," says Dr. Dougherty. "Unfortunately, 60% of people with early signs of the disease go undiagnosed until they are past the early stages, when treatment options are best. Our goal was to make low-cost screening available to the general public so they can monitor their cognitive health, just as they would monitor blood pressure or blood sugar levels."
The ALZselftest, which can be taken in about 10 minutes, costs only $20, about as much as a co-pay, for a single use. It provides scoring information and a report, which the user can take to their doctor's office for further evaluation. For those uncomfortable with their computer skills, the test has audible directions or can be taken with the aid of a friend or family member.
Ongoing clinical studies of the ALZselftest show it is 98% accurate in distinguishing those with cognitive impairment from non-impaired persons. This rate is achieved because ALZselftest measures all of the cognitive domains, unlike other Alzheimer's tests. It also has shown 95% accuracy at distinguishing between the stages of Alzheimer's, including Mild Cognitive Impairment. By contrast, the widely used screening test, MMSE, only reaches 67% diagnostic accuracy.
In support of our mission to support early diagnosis of Alzheimerâ€™s Disease and in recognition of Alzheimer's Awareness Month, 20% of all proceeds during the month of November will be donated to the Alzheimer's Association. Following November, 10% of all proceeds will be donated.
The test, research and supporting statistical data, as well as comprehensive resources for those wishing to learn more about AD, are available at www.alzselftest.com.
About Dr. John Dougherty and Medinteract, LLC
Dr. John H. Dougherty is a leading neurologist who currently follows more than 1500 Alzheimer's patients, founder of Medical Interactive Education, Co-Director of the Brain and Spine Institute at UT Medical Center, Medical Director of the Cole Neuroscience Center at UT Medical Center in Knoxville, and the developer of the ALZselftest.